

16. (Amended) The method of claim [14] 15, wherein said cell is a cell [in accordance with one of claims 13 or 14] having been rendered multidrug resistant (MDR) by an expression of an Annexin nucleic acid molecule.

17. (Amended) The method of claim 15 [or 16], wherein said compound is selected from the group consisting of a nucleic acid molecule encoding an Annexin variant, or a part thereof, a dominant negative mutant of an Annexin, a mutant Annexin, an antibody to Annexin, a peptide, and a small molecule.

19. (Amended) The method of [one of] claim[s] 15[, 16, 17 or 18], wherein said drug is an anticancer drug.

20. (Amended) A method of reducing Annexin-based MDR in a cell comprising: administering thereto [a therapeutically] an effective amount of a compound selected from the group consisting of a nucleic acid molecule, a dominant negative mutant of an Annexin, a mutant Annexin protein, an antibody to Annexin, a peptide, and a small molecule, whereby said effective amount of said compound reduces Annexin-based MDR in said cell.

26. (Amended) A method of diagnosing the presence or predisposition of Annexin-based MDR in a [patient] sample comprising:

- (a) taking a sample from said patient;]
- (b)] a) determining the amount of Annexin protein and/or nucleic acid in said sample; and
- [c)] b) diagnosing the presence or predisposition of Annexin-based MDR in said [patient] sample, wherein an increased amount of said Annexin protein and/or nucleic acid in said sample as compared to a control sample indicates the presence or predisposition towards Annexin-based MDR.

Please add the following new claims:

AS  
--30. The method of claim 27, wherein said sample is from a patient.

31. The method of claim 27, wherein said sample is a sample from a pathogen.--


Affirmation is hereby given by the foregoing, that claims 1-5; 8-14; and 28-29 have been withdrawn from further consideration. Applicants reserve the right to prosecute the subject-matter thereof by way of a divisional.

Applicant respectfully requests that the preliminary amendment described herein be entered into the record prior to examination and consideration of the above-identified application.

Respectfully submitted,

QUARLES & BRADY

by:



Jean C. Baker  
Registration No. 35,433

Date: April 20, 2000

QUARLES & BRADY  
411 East Wisconsin Avenue  
Milwaukee WI 53202-4497  
U.S.A.  
(414) 277-5709